These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Olanzapine usage associated with neuroleptic malignant syndrome. Philibert RA; Adam LA; Frank FM; Carney-Doebbeling C Psychosomatics; 2001; 42(6):528-9. PubMed ID: 11815691 [No Abstract] [Full Text] [Related]
43. Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia. Aboraya A; Schumacher J; Abdalla E; LePage J; McGhee M; Butcher D; Griffin H; Shahda M W V Med J; 2002; 98(2):63-5. PubMed ID: 12048741 [TBL] [Abstract][Full Text] [Related]
44. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. Lee JW J Clin Psychopharmacol; 2010 Feb; 30(1):3-10. PubMed ID: 20075641 [TBL] [Abstract][Full Text] [Related]
45. Olazapine induced neuroleptic malignant syndrome. Zaragoza Fernández M; Torres García E Actas Esp Psiquiatr; 2006; 34(2):144-5. PubMed ID: 16552643 [No Abstract] [Full Text] [Related]
47. Olanzapine-induced diabetes in a seven-year-old boy. Courvoisie HE; Cooke DW; Riddle MA J Child Adolesc Psychopharmacol; 2004; 14(4):612-6. PubMed ID: 15662154 [TBL] [Abstract][Full Text] [Related]
48. Neuroleptic malignant syndrome following reintroduction of an antipsychotic after overdose. Korchia T; Blackman G; Cermolacce M; Richieri R BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30076161 [TBL] [Abstract][Full Text] [Related]
49. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome. Liu PY; Wu PC; Chen CY; Chen YC Gen Hosp Psychiatry; 2011; 33(1):84.e5-7. PubMed ID: 21353143 [TBL] [Abstract][Full Text] [Related]
50. Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report. Chang CK; Payus AO; Noh MM; Lansing MG; Sumpat D; Lu SJA; Yew BT J Med Case Rep; 2022 Oct; 16(1):366. PubMed ID: 36203196 [TBL] [Abstract][Full Text] [Related]
51. [Rabbit syndrome due to olanzapine]. Sabolek M; Bayerle M Psychiatr Prax; 2005 May; 32(4):202-4. PubMed ID: 15852213 [TBL] [Abstract][Full Text] [Related]
53. Neuroleptic malignant syndrome associated with olanzapine. Johnson V; Bruxner G Aust N Z J Psychiatry; 1998 Dec; 32(6):884-6. PubMed ID: 10084355 [TBL] [Abstract][Full Text] [Related]
54. Atypical (olanzapine) plus conventional (fluphenazine) neuroleptic treatment associated with the neuroleptic malignant syndrome. Tofler IT; Ahmed B J Clin Psychopharmacol; 2003 Dec; 23(6):672-4. PubMed ID: 14624203 [No Abstract] [Full Text] [Related]
55. Amisulpride and neuroleptic malignant syndrome. Tu MC; Hsiao CC Chang Gung Med J; 2011; 34(5):536-40. PubMed ID: 22035899 [TBL] [Abstract][Full Text] [Related]
56. Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment. Oglodek E; Szota A; Araszkiewicz A Aust N Z J Psychiatry; 2013 Oct; 47(10):972. PubMed ID: 23630396 [No Abstract] [Full Text] [Related]
57. Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report. Malyuk R; Gibson B; Procyshyn RM; Kang N Int J Geriatr Psychiatry; 2002 Apr; 17(4):326-8. PubMed ID: 11994885 [TBL] [Abstract][Full Text] [Related]